Coastar Therapeutics
Coastar Therapeutics is a San Diego-based biotech company dedicated to developing biological payload delivery technologies for cancer and gene therapies. Their proprietary ENHEnSTM technology coats cell membranes on biological payloads to evade immune recognition and deliver to disease sites, aiming to improve efficacy, reduce toxicity, and lower treatment costs. The company is actively involved in advancing gene and cell therapy delivery systems, collaborating with global partners, and participating in industry conferences to showcase their innovative solutions.
Industries
Nr. of Employees
small (1-50)
Coastar Therapeutics
San Diego, California, United States, North America
Patents
Products
Erythrocyte-derived membrane nanocarrier platform
A platform that uses erythrocyte-derived cell membranes to coat biological payloads, intended to reduce immune clearance and enable targeted delivery of therapeutics.
ENHEnS™
An innovative cell membrane coating technology platform that enables a wide range of biological payloads to avoid immune clearance and be successfully delivered to disease sites, increasing efficacy, reducing toxicity, lowering cost, and expanding applications in cancers and other diseases.
ENHEnS TM
Proprietary technology that can coat cell membranes on biological payloads to help them evade recognition and clearance by the immune system and be successfully targeted to tumor or other disease sites.
Erythrocyte Derived Membrane (EDM) gene delivery technology
Proprietary gene delivery technology designed to enable targeted, efficient, and scalable delivery of DNA/RNA therapeutics using engineered red blood cell–derived membranes.
Erythrocyte-derived membrane nanocarrier platform
A platform that uses erythrocyte-derived cell membranes to coat biological payloads, intended to reduce immune clearance and enable targeted delivery of therapeutics.
ENHEnS™
An innovative cell membrane coating technology platform that enables a wide range of biological payloads to avoid immune clearance and be successfully delivered to disease sites, increasing efficacy, reducing toxicity, lowering cost, and expanding applications in cancers and other diseases.
ENHEnS TM
Proprietary technology that can coat cell membranes on biological payloads to help them evade recognition and clearance by the immune system and be successfully targeted to tumor or other disease sites.
Erythrocyte Derived Membrane (EDM) gene delivery technology
Proprietary gene delivery technology designed to enable targeted, efficient, and scalable delivery of DNA/RNA therapeutics using engineered red blood cell–derived membranes.
Services
Co-development and licensing collaborations to apply membrane-derived delivery technologies to partner therapeutic programs (viral and non-viral payloads).
Design, qualification, and transfer of cellular and enzyme-based bioassays and QC-suitable analytical methods to support in-process control, release testing, and pilot process development.
Optimization and scale-up of processes for membrane-material production and biologic payloads, including pilot-scale process development and technical transfer to manufacturing partners.
Support for cGMP-compliant operations including equipment commissioning, troubleshooting, validation support, and preparation for regulatory audits.
Generation of preclinical efficacy and safety data and coordination of studies necessary to advance therapeutic candidates toward IND-enabling packages.
Co-development and licensing collaborations to apply membrane-derived delivery technologies to partner therapeutic programs (viral and non-viral payloads).
Design, qualification, and transfer of cellular and enzyme-based bioassays and QC-suitable analytical methods to support in-process control, release testing, and pilot process development.
Optimization and scale-up of processes for membrane-material production and biologic payloads, including pilot-scale process development and technical transfer to manufacturing partners.
Support for cGMP-compliant operations including equipment commissioning, troubleshooting, validation support, and preparation for regulatory audits.
Generation of preclinical efficacy and safety data and coordination of studies necessary to advance therapeutic candidates toward IND-enabling packages.
Expertise Areas
- Gene delivery and nanocarrier platforms
- Oncolytic virotherapy delivery
- Viral vector (AAV, lentivirus) production and characterization
- In vivo and in vitro genome-editing delivery
Key Technologies
- Erythrocyte-derived membrane nanocarriers (cell membrane coating)
- Oncolytic virus delivery
- AAV vector delivery
- Lentiviral transduction and production
News & Updates
The company announced its participation at the BIO International Convention, June 13-16, 2022, where it showcased its innovative delivery technology.
On June 30, 2021, Coastar announced the successful closing of its seed funding round to accelerate R&D programs.
On October 1, 2024, Coastar announced its participation in JLABS, an early-stage biotech accelerator of Johnson & Johnson.
On November 5, 2024, Coastar was nominated for the prestigious Prix Galien USA Award, recognizing excellence in biotech innovation.
The company announced its participation at the BIO International Convention, June 13-16, 2022, where it showcased its innovative delivery technology.
On June 30, 2021, Coastar announced the successful closing of its seed funding round to accelerate R&D programs.
On October 1, 2024, Coastar announced its participation in JLABS, an early-stage biotech accelerator of Johnson & Johnson.
On November 5, 2024, Coastar was nominated for the prestigious Prix Galien USA Award, recognizing excellence in biotech innovation.